Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Polycythemia Vera 3Thrombocythemia, Essential 2Philadelphia Chromosome 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Brain Neoplasms 2Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Leukemia 1Glioma 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1Blast Crisis 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 175Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × peginterferon alfa-2a × Clear all
NCT00227656 2012-12-11

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡